Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Clinical trial NCT04260009 · WITHDRAWN

Trial details

NCT number: NCT04260009
Sponsor: Takeda
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma Inflammatory Myofibroblastic Tumors Solid Tumors

Start date: 2020-09-01
Primary completion: 2023-09-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.